TMTPOST -- Novo Nordisk A/S shares plummeted as much as 27%, wiping up to $125 billion off in the market value, and settled 20.8% lower on Friday. Shares registered their worst day since listing in 2002 after the Danish drugmaker released disappointing trail results for its experimental...
Market Screener Sectors Search Ticker | NVOU.S.: NYSE +Watchlist You must be logged in to create alerts After Hours Last Updated:Jan 24, 2025 7:59 p.m.ESTDelayed quote $87.86 -0.11-0.13% After Hours Volume:881.59K CloseChgChg % ...
The shares rally came after Chinese regulator greenlit sales of Wegovy, Novo Nordisk’s blockbuster weight-loss drug. It highlighted how optimistic investors felt on the company’s expansion into China, the world’s second largest economy and the second most populous country. China is projected to...
As of June 2024 Novo Nordisk has a market cap of $623.24 Billion. This makes Novo Nordisk the world's 11th most valuable company according to our data.
Market Screener Sectors Search Ticker | NVOU.S.: NYSE +Watchlist You must be logged in to create alerts After Hours Last Updated:Jan 24, 2025 7:59 p.m.ESTDelayed quote $87.86 -0.11-0.13% After Hours Volume:881.59K CloseChgChg % ...
Market Screener Sectors Search Ticker | NVOU.S.: NYSE +Watchlist You must be logged in to create alerts After Hours Last Updated:Jan 24, 2025 7:59 p.m.ESTDelayed quote $87.86 -0.11-0.13% After Hours Volume:881.59K CloseChgChg % ...
Thank you, Camilla. Please turn to the next slide. Sales in North America were driven by a prescription volume growth of the GLP-1 class above 15% in the third quarter of 2024 compared with the third quarter of 2023, as well as Novo Nordisk market share gains. Sales of GLP-1 diabetes...
Lilly is now the “preeminent player in the market,” Mizuho’s Jared Holz said in a note. Citi analyst Geoffrey Meacham called it “nearly a best-case scenario” because Novo’s shot could have eroded Lilly’s market share in the heaviest patients....
Novo Nordisk A/S Novo Allé 1 Bagsværd, CR 2880 Phone45 44 448-888 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2024 Revenuekr.232.26B Net Incomekr.83.68B 2023 Sales Growth31.26% Employees63,370 Biography ...
Novo Nordisk A/S Quarterly cash flow by MarketWatch. View NOVO.B net cash flow, operating cash flow, operating expenses and cash dividends.